Skip to main content
SpringerLink
Log in

Plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation: a profile of its use in the USA

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Plecanatide (Trulance®), a guanylate cyclase C agonist, is an effective and generally well-tolerated treatment option for adults with chronic idiopathic constipation or irritable bowel syndrome with constipation. It can be administered with or without food, at any time of the day. In phase 3 clinical trials, once-daily plecanatide 3 mg significantly improved stool frequency, stool consistency, clinical symptoms (e.g. straining, abdominal symptoms including pain), health-related quality of life, and treatment satisfaction. Plecanatide is generally well tolerated, with most adverse events being of mild or moderate severity. Consistent with its therapeutic action, the most common adverse event is diarrhea.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chey WD. Symposium report: an evidence-based approach to IBS and CIC: applying new advances to daily practice: a review of an adjunct clinical symposium of the American College of Gastroenterology meeting October 16, 2016, Las Vegas, Nevada. Gastroenterol Hepatol. 2017;13(2 Suppl 1):1–16.

    Google Scholar 

  2. Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58(9):2580–6.

    Article  CAS  Google Scholar 

  3. Waldman SA, Camilleri M. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut. 2018;67(8):1543–52.

    Article  Google Scholar 

  4. Trulance (plecanatide) tablets: US prescribing information. New York: Synergy Pharmaceuticals Inc. 2018.

  5. Shailubhai K, Palejwala V, Arjunan KP, et al. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther. 2015;6(4):213–22.

    Article  Google Scholar 

  6. Shailubhai K, Beaufrand C, Palejwala V, et al. Oral treatment with plecanatide and SP-333, agonists of guanylate cyclase-C, attenuates visceral hypersensitivity in rat models (abstract no. PP095). Neurogastroenterol Motil. 2014;26:Suppl 1–41.

    Google Scholar 

  7. Miner PB Jr, Koltun WD, Wiener GJ, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112:613–21.

    Article  CAS  Google Scholar 

  8. DeMicco M, Barrow L, Hickey B, et al. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Ther Adv Gastroenterol. 2017;10(11):837–51.

    Article  CAS  Google Scholar 

  9. Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018;113(5):735–45.

    Article  CAS  Google Scholar 

  10. Rao S, Barrow L, Layton MB. Efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation (CIC): pooled results from two phase 3 studies (abstract no. 523). Am J Gastroenterol. 2016;111(Suppl 1):S237.

    Google Scholar 

  11. Rao SS, Hixson MA, Mikhelashvili T. The impact of plecanatide on quality of life for patients with chronic idiopathic constipation (CIC): results from two phase 3 clinical studies (abstract no. PGI39 + poster). Value Health. 2017;20(5):A186–7.

    Google Scholar 

  12. Rao SS, Griffin P, Magnus L. Efficacy and safety of plecanatide in patients with chronic idiopathic constipation: an analysis of patients with moderate to very severe bloating (abstract no. Su1517 + poster). Gastroenterology. 2017;152((5 Suppl 1)):S507.

    Article  Google Scholar 

  13. Moshiree B, Magnus L, Rezaie A. Acid suppression therapy does not affect the efficacy of plecanatide: a patient-level pooled analysis of two large randomized controlled trials (abstract no. P1222). In: American College of Gastroenterology Scientific Meeting & Postgraduate Course. 2018.

  14. Menees SB, Chey WD, Crozier R. Evaluation of the safety and tolerability of plecanatide in CIC and IBS-C patients aged 65 and older (abstract no. P0335). In: American College of Gastroenterology Annual Scientific Meeting & Postgraduate Course. 2018.

  15. Barish CF, Griffin P. Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study. Curr Med Res Opin. 2018;34(4):751–5.

    Article  CAS  Google Scholar 

  16. Barish CF, Crozier RA, Griffin PH. Long-term treatment with plecanatide was safe and tolerable in patients with irritable bowel syndrome with constipation. Curr Med Res Opin. 2018. https://doi.org/10.1080/03007995.2018.1527303 (e-pub).

    Article  PubMed  Google Scholar 

  17. Harris LA, Horn J, Kissous-Hunt M, et al. The better understanding and recognition of the disconnects, experiences, and needs of patients with chronic idiopathic constipation (BURDEN-CIC) study: results of an online questionnaire. Adv Ther. 2017;34(12):2661–73.

    Article  Google Scholar 

  18. Quigley EMM, Horn J, Kissous-Hunt M, et al. Better understanding and recognition of the disconnects, experiences, and needs of patients with irritable bowel syndrome with constipation (BURDEN IBS-C) study: results of an online questionnaire. Adv Ther. 2018;35(7):967–80.

    Article  Google Scholar 

  19. Linzess (linaclotide) capsules: US prescribing information. Irvine (CA): Allergan USA, Inc.; 2017.

  20. Amitiza (lubiprostone) capsules: US prescribing information. Deerfield (IL): Takeda Pharmaceuticals America, Inc.; 2018.

  21. Black CJ, Burr NE, Quigley EMM, et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018. https://doi.org/10.1053/j.gastro.2018.08.021 (e-pub).

    Article  PubMed  Google Scholar 

  22. Lasa JS, Altamirano MJ, Bracho LF, et al. Efficacy and safety of intestinal secretagogues for chronic constipation: a systematic review and meta-analysis. Arq Gastroenterol. 2018. https://doi.org/10.1590/s0004-2803.201800000-41 (e-pub).

    Article  PubMed  Google Scholar 

  23. Shah ED, Kim HM, Schoenfeld P. Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis. Am J Gastroenterol. 2018;113(3):329–38.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: C. F. Barish, Gastroenterology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; L. A. Harris, Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ, USA; Y-M. Huang, Division of Social and Administrative Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA; I. Zaghloul, Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA. During the peer review process, Synergy Pharmaceuticals, the marketing-authorization holder of plecanatide, was offered an opportunity to provide a scientific accuracy review of the data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Hannah A. Blair

Authors
  1. Hannah A. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah A. Blair.

Ethics declarations

Conflicts of interest

H A. Blair is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blair, H.A. Plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation: a profile of its use in the USA. Drugs Ther Perspect 34, 554–559 (2018). https://doi.org/10.1007/s40267-018-0579-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0579-y

Search

Navigation